The Trump administration announced that it will end a temporary Medicare prescription drug subsidy program after 2026, concluding that insurers no longer need billions of dollars in taxpayer support to keep premiums stable. The Centers for Medicare and Medicaid Services said the Part D Premium Stabilization Demonstration, created by the Biden administration in 2024, successfully helped insurers adjust to major changes made under the Inflation Reduction Act. However, it will expire as scheduled at the end of next year.

CMS said insurers have now gained enough experience with the redesigned Medicare Part D benefit to accurately price their plans without additional federal assistance. As a result, the program will return to normal market conditions beginning in 2027. The agency projects the national base beneficiary premium will increase from $38.99 in 2026 to $41.33 in 2027, although officials said most enrollees will see premium increases of less than $10 per month and some could pay less.

The administration also argued that ending the subsidies supports President Trump’s effort to reduce taxpayer-funded payments to insurance companies while pursuing lower prescription drug prices.

The subsidy has played a major role in holding down Medicare Part D premiums during the transition to the redesigned drug benefit. The Medicare Payment Advisory Commission estimated in a March report that the subsidy lowered the average stand-alone Part D premium from $65 to $39 per month in 2025, a 40% reduction after accounting for the separate statutory premium cap. As of 2026, the projected average has been lowered from $60 to $44, or roughly 27%…

A company called Cytonics is attempting to change the biology of osteoarthritis — a $560 billion market where every existing treatment does nothing but manage symptoms while the cartilage keeps deteriorating.

Cytonics discovered that your blood contains a protein designed to protect your joints from the enzymes that destroy cartilage. Your body just doesn't produce enough of it. So they engineered a synthetic version that can be mass-produced.

More than 10,000 patients have been treated with their first-generation therapy. The new version — 200% more potent — just cleared Phase 1 human safety trials with zero adverse events.

If it works, this would be the first disease-modifying osteoarthritis treatment in history. The first one. Ever.*

You can see the full details — and invest — by clicking here.

There are nearly 24.9 million people enrolled in stand-alone Part D plans. Although CMS expects most beneficiaries to face increases of less than $10 and some to pay less, the national base premium is still projected to rise about 6% in 2027. While the increases aren’t huge jumps, they do add another variable when shopping for plans, especially for Americans living on a fixed income or those with multiple prescriptions.

For anyone relying on Medicare Part D, these changes make reviewing your prescription drug coverage during the annual enrollment period a bit more important. While CMS expects most beneficiaries to see relatively modest premium increases, the amount you actually pay will depend on the specific plan you choose, where you live, and the medications you take.

Comparing plans instead of automatically renewing your current coverage could result in meaningful savings if insurers adjust premiums, deductibles, or formularies after the subsidies expire.

The policy also has big implications for how future Medicare benefits are financed. Billions of dollars in payments to insurers have been ended, and the Trump administration is indicating that temporary government support should not become a permanent feature of the program. If competition among insurers remains strong, beneficiaries are likely to continue to see stable premiums without additional taxpayer funding.

However, should costs rise faster than expected, lawmakers may face added pressure to revisit the program's design or pursue other reforms aimed at controlling prescription drug spending while protecting seniors from higher out-of-pocket costs.

*Disclaimer: This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://invest.cytonics.com. Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.